Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML [Phase 2]
Clinical trial update on a Phase 2 study of mitoxantrone hydrochloride liposome with cytarabine and venetoclax in newly diagnosed elderly ac…
-
CLINICAL_TRIALS research · 2024-09-25Clinical Trial Update: Twice-per-weekSelinexor, 2 Days Melphalan [Phase 3]
Phase 3 trial of twice-weekly selinexor with two days of melphalan for acute myeloid leukemia; study status is not yet recruiting.
-
CLINICAL_TRIALS research · 2024-09-25Clinical Trial Update: Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Expanded access program for GL-ONC1 in patients with advanced solid tumors and acute myeloid leukemia is no longer available.
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy [NA]
This clinical trial evaluated remote outpatient temperature monitoring for early detection of febrile neutropenia in patients undergoing che…
-
CLINICAL_TRIALS research · 2024-09-20Clinical Trial Update: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
ClinicalTrials.gov entry describing an active-but-not-recruiting study evaluating immunogenicity and the immunological effects of hypomethyl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) [Phase 3]
Phase 3 trial evaluating gilteritinib as maintenance therapy after allogeneic transplant in FLT3-ITD acute myeloid leukemia. The study has c…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients [Phase 2]
Phase IIa study evaluating the safety and efficacy of BL-8040 in relapsed/refractory acute myeloid leukemia has completed. Results have been…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Phase 1 First in Human Study of ZN-d5 as a Single Agent [Phase 1]
Phase 1 first-in-human trial of ZN-d5 as a single agent has completed, with study conducted in patients with acute myeloid leukemia and non-…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS [Phase 1]
A Phase 1 trial of magrolimab in combination with azacitidine after allogeneic hematopoietic cell transplantation in high-risk acute myeloid…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma [Phase 1]
Phase 1 trial evaluating the combination of CPI-613 (devimistat) with cytarabine and mitoxantrone hydrochloride in relapsed or refractory ac…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
A Phase 1/2 trial evaluating venetoclax plus quizartinib in FLT3-mutated acute myeloid leukemia was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) [Phase 1]
Phase 1 clinical trial evaluating clifutinib in patients with relapsed or refractory acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS [Phase 1]
Phase I study of CYC140, a PLK-1 inhibitor, in advanced leukemias and myelodysplastic syndromes has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS [Phase 1]
This Clinical Trial Update reports that a Phase 1 study of CYC065 in combination with Venetoclax for relapsed or refractory acute myeloid le…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients [Phase 2]
Phase 2 clinical trial evaluating tolerability and efficacy of adding midostaurin to a 10-day decitabine regimen in unfit adults with acute …
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]
A Phase 2 clinical trial evaluating CPI-613 (devimistat) in combination with metformin for relapsed or refractory acute myeloid leukemia has…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT [Phase 2]
This is a Phase 2 trial evaluating IDH2-mutant myeloid neoplasms after allogeneic stem cell transplantation. The study status is completed.
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial evaluating total marrow and lymphoid irradiation (TMLI) with chemotherapy for high-risk myelodysplastic syndromes a…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
The clinical trial studying ZN-d5 and ZN-c3 in acute myeloid leukemia was terminated; no results are provided in the update.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Tislelizumab with Azacitidine in the Treatment of R/R AML [Phase 1, Phase 2]
This clinical trial update notes the phase 1/2 study of tislelizumab with azacitidine for refractory or relapsed acute myeloid leukemia has …
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia. [Phase 2]
Phase 2 clinical trial evaluating total marrow irradiation-based conditioning with fludarabine and melphalan for allogeneic transplantation …
-
CLINICAL_TRIALS trial_result · 2024-09-05Clinical Trial Update: Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
Phase 1/2 trial of BL-8040 plus atezolizumab as maintenance therapy in acute myeloid leukemia; the study was terminated and results were pos…
-
CLINICAL_TRIALS trial_result · 2024-09-05Clinical Trial Update: A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems [Phase 1]
Takeda announced results from a Phase 1 study of pevonedistat in people with blood cancers and solid tumors who also have kidney or liver im…
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening [Phase 2]
A Phase 2 study evaluating the combination of venetoclax and azacitidine in AML patients selected by ex vivo drug sensitivity screening has …
-
CLINICAL_TRIALS trial_result · 2024-09-03Clinical Trial Update: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma [Phase 1]
Pfizer's Phase 1 trial of Maplirpacept (PF-07901801) in advanced hematologic malignancies, including diffuse large B-cell lymphoma, acute my…